NSPR - InspireMD, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
2.9300
+0.0500 (+1.74%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close2.8800
Open2.9900
Bid2.3000 x 800
Ask3.0700 x 1000
Day's Range2.6700 - 3.1800
52 Week Range1.9000 - 15.5000
Volume88,527
Avg. Volume65,232
Market Cap4.394M
Beta (3Y Monthly)3.45
PE Ratio (TTM)N/A
EPS (TTM)-9.9060
Earnings DateNov 4, 2019 - Nov 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    InspireMD Announces Notification of NYSE AMERICAN Listing Deficiency

    InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that it has received a letter from the NYSE American on August 7, 2019, indicating that InspireMD does not meet a certain NYSE American LLC (the “NYSE American”) continued listing standard as set forth in Part 10, Section 1003(a)(iii) of the Company Guide of the NYSE American, due to the fact the Company had reported stockholders’ equity of less than $6 million as of June 30, 2019, and had net losses in its five most recent fiscal years ended December 31, 2018. The Exchange's notice has no immediate effect on the listing of the Company's common stock on the Exchange.

  • Thomson Reuters StreetEvents

    Edited Transcript of NSPR earnings conference call or presentation 6-Aug-19 12:00pm GMT

    Q2 2019 InspireMD Inc Earnings Call

  • GlobeNewswire

    InspireMD Announces Second Quarter 2019 Financial Results

    U.S. Investigational Device Exemption (IDE) application submitted to FDA Company to host investor conference call today, August 6, at 8:00am ET TEL AVIV, Israel, Aug. 06,.

  • GlobeNewswire

    InspireMD to Report Second Quarter 2019 Financial Results and Provide Business Update on Tuesday, August 6

    TEL AVIV, Israel, July 30, 2019 -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the.

  • InspireMD (NSPR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
    Zacks

    InspireMD (NSPR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

    InspireMD (NSPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Do Institutions Own InspireMD, Inc. (NYSEMKT:NSPR) Shares?
    Simply Wall St.

    Do Institutions Own InspireMD, Inc. (NYSEMKT:NSPR) Shares?

    A look at the shareholders of InspireMD, Inc. (NYSEMKT:NSPR) can tell us which group is most powerful. Institutions...

  • Thomson Reuters StreetEvents

    Edited Transcript of NSPR earnings conference call or presentation 14-May-19 12:00pm GMT

    Q1 2019 InspireMD Inc Earnings Call

  • GlobeNewswire

    InspireMD Announces First Quarter 2019 Financial Results

    On-Track to Submit U.S. IDE expected in Mid-2019 Company to Host Investor Conference Call at 8:00am ET TEL AVIV, Israel, May 14, 2019 -- InspireMD, Inc. (NYSE American:.

  • GlobeNewswire

    InspireMD to Report First Quarter 2019 Financial Results and Provide Business Update on Tuesday, May 14

    TEL AVIV, Israel, May 07, 2019 -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the.

  • GlobeNewswire

    InspireMD, Inc. Announces Pricing of $2.4 Million Public Offering of Common Stock

    InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced the pricing of its previously announced underwritten public offering of 486,957 shares of its common stock at a price to the public of $5.00 per share. The offering is expected to close on or about April 8, 2019, subject to customary closing conditions.  InspireMD also granted the underwriter a 30-day option to purchase an additional 73,043 shares of its common stock. H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

  • GlobeNewswire

    InspireMD, Inc. Announces Proposed Public Offering of Common Stock

    InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. InspireMD also expects to grant the underwriter a 30-day option to purchase additional shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • ACCESSWIRE

    A Reverse Split and Key Demand Drivers for InspireMD's Proprietary Technology

    NEW YORK, NY / ACCESSWIRE / April 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuinga comprehensive report on InspireMD, Inc. (NSPR), a biotechnology company that has developed a portfolio of medical device assets using a proprietary technology called MicroNet. CGuard EPS is the company's lead product, and it's a highly differentiated, minimally invasive treatment for carotid artery disease designed around its proprietary and elegantly simple MicroNet technology to dramatically reduce or even eliminate the incidence of stroke following carotid artery procedures.

  • GlobeNewswire

    InspireMD Announces 1-for-50 Reverse Stock Split

    InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its Board of Directors has approved a one-for-fifty reverse stock split of its common stock that is scheduled to become effective after trading closes on March 29, 2019. Beginning on April 1, 2019, the Company’s common stock will trade on the NYSE American on a split adjusted basis under a new CUSIP number 45779A 853. The Company’s common stock will continue to trade on the NYSE American under the symbol “NSPR.” As previously disclosed, at the InspireMD Annual Meeting of Stockholders held on March 21, 2019, the Company’s stockholders approved a proposal authorizing the Company’s Board of Directors to effect a reverse stock split at a ratio in the range of one-for-twenty-five and one-for-fifty in order to help regain compliance with the NYSE American’s minimum price requirements.

  • GlobeNewswire

    InspireMD Provides Amended Disclosure

    InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today provided an amended disclosure to conform to the Company’s Form 10-K that was filed with the SEC on February 19, 2019. As disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, which was filed on February 19, 2019 with the Securities and Exchange Commission, the audited financial statements contained a going concern qualification paragraph in the audit opinion from its independent registered public accounting firm.  See further discussion in Note 1 to the Company’s consolidated financial statements included in the Company’s Annual Report on Form 10-K. This announcement is made pursuant to NYSE American Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph.

  • GlobeNewswire

    InspireMD Announces Fourth Quarter 2018 Financial Results

    2018 CGuard™ EPS annual sales increased 55% compared to 2017 On-Track to Submit U.S. IDE in Mid-2019 Company to Host Investor Conference Call at 8:00am ET TEL AVIV, Israel,.

  • GlobeNewswire

    InspireMD to Report Fourth Quarter and Fiscal 2018 Financial Results and Provide Business Update on Tuesday, February 19

    TEL AVIV, Israel, Feb. 07, 2019 -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the.

  • GlobeNewswire

    InspireMD Announces Presentation of Interim Data from Investigator-Initiated Study Comparing CGuard™ EPS with a Conventional Open-Cell Carotid Stent

    CGuard™ EPS shows encouraging interim results verses a conventional carotid stent in absence of any adverse clinical events in the CGuard™ arm Data presented at the LINC 2019.

  • GlobeNewswire

    InspireMD Announces Two Successful Live Clinical Case Transmissions Featuring CGuard™ EPS at the Leipzig Interventional Course (LINC) 2019

    InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that two successful live cases featuring CGuard™ EPS were presented at LINC 2019, which is being held January 21 – 23 in Leipzig, Germany. “The live demonstrations of CGuard™ EPS at this year’s LINC conference, a major international interventional conference covering the latest innovations in vascular medicine, allowed attending physicians to see first-hand the simplicity of the CGuard EPS procedure as conducted by world renowned interventional cardiologists and angiologists,” said Dr. James Barry, President and Chief Executive Officer of InspireMD.

  • GlobeNewswire

    InspireMD Announces Results from Initial Clinical Study of The CGuard™ Embolic Prevention System (EPS) with SmartFit™ Technology

    InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced details of a new investigator-initiated trial entitled, “Initial Clinical Study of the New CGuard™ EPS MicroNet® Covered Carotid Stent: ‘One Size Fits All,’” at the Leipzig Interventional Course (LINC), which is being held January 22-25, 2019 in Leipzig, Germany. “One of the keys to successfully treating patients with carotid artery disease is to employ a device that is optimally sized,” commented Prof. Wissgott.

  • GlobeNewswire

    InspireMD’s CGuard™ Embolic Prevention System to be Prominently Featured in Live Case Transmissions at LINC, 22nd to the 25th January 2019, in Leipzig, Germany

    TEL AVIV, Israel, Jan. 18, 2019 -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,.

  • GlobeNewswire

    InspireMD Announces the Distribution of CGuard™ Embolic Prevention System in South Africa

    InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that its novel CGuard EPS will be distributed by its local distribution partner, Torque Medical of Roodepoort, Johannesburg. Craig Goodburn, Managing Member of Torque Medical, commented, “We are extremely pleased with the opportunity to offer CGuard EPS in the South African market.

  • GlobeNewswire

    InspireMD Receives Noncompliance Notice from NYSE American

    InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that on January 7, 2019, the Company received a letter from NYSE American LLC (“NYSE American”) stating that it is not in compliance with the continued listing standards as set forth in Part 10, Section 1003(f)(v) of the NYSE American Company Guide (the “Company Guide”) due to the Company’s current low selling share price.

  • GlobeNewswire

    InspireMD Announces Publication of Meta-Analysis Citing Benefits of Next Generation Mesh-Covered Carotid Stent Systems

    InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced the publication of a meta-analysis of four clinical studies involving dual layered and mesh-covered stents in the December 10, 2018 issue of JACC: Cardiovascular Interventions. The analysis concluded that carotid artery disease (CAD) patients treated with mesh-covered stents experienced a 30-day minor stroke rate of 1.25%, lower than 30-day minor stroke rates reported in other widely cited studies, such as CREST and ACT 1, for patients treated with both carotid endarterectomy (CEA) and with those treated with conventional carotid stents.

  • Simply Wall St.

    What Investors Should Know About InspireMD, Inc.’s (NYSEMKT:NSPR) Financial Strength

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like InspireMD, Inc. (NYSEMKT:NSPR), as the company does not have to adhere to strict debt covenants. However, it also faces higher Read More...

  • GlobeNewswire

    InspireMD Announces Positive Long-Term Safety and Efficacy Data from Ongoing CGuard™ EPS Registries at the Recent 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)

    The results of three separate registries confirm the long-term benefits of CGuard™ EPS in preventing late embolic events. In his presentation, Piotr Musialek, MD, DPhil, Jagiellonian University Professor of Cardiovascular Medicine, Jagiellonian University Dept. of Cardiac & Vascular Diseases, John Paul II Hospital, Krakow, Poland, presented an update of his ongoing PARADIGM-Extend clinical trial of “all comers” with high-risk carotid stenosis in 251 patients treated with CGuard™ EPS.